(Total Views: 734)
Posted On: 09/12/2020 9:14:59 AM
Post# of 148903
Good day,
I tend to agree with you.
We need an approval or an EUA and then the dam will tumble down. If FDA decides to put us through P3 for M2M the interim of CD12 will be the decider. Everything else will come as a direct consequence of these results (CD12).
We are close to the 28 days and the primary end point p-value can be obtained relatively quick.
In any case, we are about to find out were do we stand in the COVID world to paraphrase Dr. Patterson. There is NO drug approved after clinical trials for COVID. Shall we be the first, the SP in single digits will be thing of the past.
While we wait on the CRITICAL and likely blockbuster CD12 results we have:
Possible CD10 EUA (low probability imho)
Possible BLA filing in the U.K.
Possible up-list to NASDAQ
Possible peer-reviewed publication of Dr. Patterson paper.
I say we are sitting pretty here.
You all have a good weekend.
I tend to agree with you.
We need an approval or an EUA and then the dam will tumble down. If FDA decides to put us through P3 for M2M the interim of CD12 will be the decider. Everything else will come as a direct consequence of these results (CD12).
We are close to the 28 days and the primary end point p-value can be obtained relatively quick.
In any case, we are about to find out were do we stand in the COVID world to paraphrase Dr. Patterson. There is NO drug approved after clinical trials for COVID. Shall we be the first, the SP in single digits will be thing of the past.
While we wait on the CRITICAL and likely blockbuster CD12 results we have:
Possible CD10 EUA (low probability imho)
Possible BLA filing in the U.K.
Possible up-list to NASDAQ
Possible peer-reviewed publication of Dr. Patterson paper.
I say we are sitting pretty here.
You all have a good weekend.
(10)
(0)Scroll down for more posts ▼
